<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02275923</url>
  </required_header>
  <id_info>
    <org_study_id>REEF</org_study_id>
    <nct_id>NCT02275923</nct_id>
  </id_info>
  <brief_title>Reveal LINQ™ Evaluation of Fluid</brief_title>
  <acronym>REEF</acronym>
  <official_title>Reveal LINQ™ Evaluation of Fluid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the use of subcutaneous impedance measured with
      an implanted Medtronic Reveal LINQ™ insertable cardiac monitor for use as a fluid status
      monitor in hemodialysis patients. The study will measure the changes in subject subcutaneous
      impedance and compare with the fluid status assessed by the volume removed from the
      hemodialysis subject during dialysis sessions. Subcutaneous impedance trends will also be
      evaluated between dialysis sessions.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated as sufficient data was collected to determine if impedance measurements with
    the LINQ™ device could track body fluid changes.
  </why_stopped>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Fluid Volume Removed</measure>
    <time_frame>24 Days</time_frame>
    <description>The average fluid volume removal during the dialysis session over all patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Subcutaneous Impedance</measure>
    <time_frame>24 days</time_frame>
    <description>The change in impedance from the beginning to the end of a dialysis session, averaged over all patients and dialysis sessions</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Diagnostic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>'Reveal LINQ™ Insertable Cardiac Monitor' will be used to measure changes in subject subcutaneous impedance and compare with the fluid status assessed by the volume removed from the hemodialysis subject during dialysis sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Reveal LINQ™ Insertable Cardiac Monitor</intervention_name>
    <description>Insertable cardiac monitor</description>
    <arm_group_label>Diagnostic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who currently undergo in-clinic hemodialysis treatment prescribed 2 or 3
             times per week

          -  Patients willing to be implanted with the Reveal LINQ™ device

          -  Patients greater than 21 years of age

          -  Patients willing and able to comply with the study procedures including giving
             informed consent

        Exclusion Criteria:

          -  Patient has an active implanted cardiac medical device (e.g. IPG, ICD, CRT, etc)

          -  Patients who currently undergo home dialysis treatment

          -  Patient is enrolled in another study that could confound the results of this study,
             without documented pre-approval from a Medtronic study manager.

          -  Patient with a recent infection defined as 1) bacteremia within 60 days OR 2)
             (nonbacteremic) infection within 14 days

          -  Patient not suitable for Reveal LINQ™ implantation (e.g., severe cachexia,
             dermatologic conditions of the skin, or major medical or social conditions expected to
             reduce survival to &lt; 6 months), in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 17, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2014</study_first_posted>
  <results_first_submitted>December 18, 2015</results_first_submitted>
  <results_first_submitted_qc>April 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 5, 2019</results_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diagnostic</title>
          <description>'Reveal LINQ™ Insertable Cardiac Monitor' will be used to measure changes in subject subcutaneous impedance and compare with the fluid status assessed by the volume removed from the hemodialysis subject during dialysis sessions.
Reveal LINQ™ Insertable Cardiac Monitor: Insertable cardiac monitor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diagnostic</title>
          <description>'Reveal LINQ™ Insertable Cardiac Monitor' will be used to measure changes in subject subcutaneous impedance and compare with the fluid status assessed by the volume removed from the hemodialysis subject during dialysis sessions.
Reveal LINQ™ Insertable Cardiac Monitor: Insertable cardiac monitor</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.3" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Fluid Volume Removed</title>
        <description>The average fluid volume removal during the dialysis session over all patients.</description>
        <time_frame>24 Days</time_frame>
        <population>Enrolled patients implanted with a LINQ device that had at least one dialysis session between 7 and 30 days post-implant. Formal statistical analysis was not performed because the likelihood from the pre-specified model did not converge due to small sample size. Average fluid loss is summarized instead.</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic</title>
            <description>'Reveal LINQ™ Insertable Cardiac Monitor' will be used to measure changes in subject subcutaneous impedance and compare with the fluid status assessed by the volume removed from the hemodialysis subject during dialysis sessions.
Reveal LINQ™ Insertable Cardiac Monitor: Insertable cardiac monitor</description>
          </group>
        </group_list>
        <measure>
          <title>Average Fluid Volume Removed</title>
          <description>The average fluid volume removal during the dialysis session over all patients.</description>
          <population>Enrolled patients implanted with a LINQ device that had at least one dialysis session between 7 and 30 days post-implant. Formal statistical analysis was not performed because the likelihood from the pre-specified model did not converge due to small sample size. Average fluid loss is summarized instead.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2948" spread="683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Subcutaneous Impedance</title>
        <description>The change in impedance from the beginning to the end of a dialysis session, averaged over all patients and dialysis sessions</description>
        <time_frame>24 days</time_frame>
        <population>Patients implanted with a LINQ having at least one dialysis session between 7 and 30 days post-implant</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic</title>
            <description>'Reveal LINQ™ Insertable Cardiac Monitor' will be used to measure changes in subject subcutaneous impedance and compare with the fluid status assessed by the volume removed from the hemodialysis subject during dialysis sessions.
Reveal LINQ™ Insertable Cardiac Monitor: Insertable cardiac monitor</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Subcutaneous Impedance</title>
          <description>The change in impedance from the beginning to the end of a dialysis session, averaged over all patients and dialysis sessions</description>
          <population>Patients implanted with a LINQ having at least one dialysis session between 7 and 30 days post-implant</population>
          <units>ohm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207" spread="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects were followed on average of 4.7 months with a range of 3 to 6 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Diagnostic</title>
          <description>'Reveal LINQ™ Insertable Cardiac Monitor' will be used to measure changes in subject subcutaneous impedance and compare with the fluid status assessed by the volume removed from the hemodialysis subject during dialysis sessions.
Reveal LINQ™ Insertable Cardiac Monitor: Insertable cardiac monitor</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <description>Patient presented to the Alfred Hospital with headache, fever and photophobia. Following admission and assessment he was diagnosed with conjunctivitis and discharged on the 28th July.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <description>Patient presented to Emergency with worsening abdominal pain. A abdominal CT scan showed ischemic bowel and an evolving small bowel obstruction. The subject underwent a laparotomy and small bowel resection.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <description>Post dialysis on the 20.01.15, a thrombosed AVF was diagnosed post ultrasound and was admitted to the Alfred Hospital for a planned fistulagram and plasty. He then required an extra dialysis session.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Application site anaesthesia</sub_title>
                <description>Pt has complained of mild numbness and very occasional discomfort at the implant site since 11.04.15. R/w by Dr Scott Wilson and nil signs of infection or cause for concern. Patient happy to continue.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Seamans, Principal Clinical Research Specialist</name_or_title>
      <organization>Medtronic</organization>
      <phone>7635262835</phone>
      <email>jennifer.l.seamans@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

